Dr. Lal Pathlabs Announces Dividend and Bonus Issue Following Strong Q2FY26 Financial Results

Dr. Lal Pathlabs has caught the attention of investors with its recent announcement of a dividend and bonus issue, revealed alongside its Q2FY26 results on October 31, 2025. This development has prompted investors to consider whether it's an opportune moment to invest in the company. Let's delve into the recent updates, share price trends, and implications for shareholders regarding these financial decisions.

The Board of Directors at Dr. Lal Pathlabs has approved a second interim dividend of INR 7 per equity share, which is 70% of the face value of INR 10 each for the fiscal year 2025-26. The record date for this dividend is set for November 7, 2025, and the payment will be dispatched or credited within 30 days of its declaration, as stated in their stock exchange filing.

In addition to the dividend, Dr. Lal Pathlabs has also announced a bonus issue of equity shares in a 1:1 ratio. This means shareholders will receive one fully paid-up equity share for every existing share they hold. The record date for this entitlement will be announced later, pending necessary approvals. The company plans to issue 8,37,75,510 bonus shares amounting to Rs 83.77 crore from its Securities Premium Account.

Following this bonus issue, Dr. Lal Pathlabs' issued, subscribed, and paid-up capital will double from Rs 83.77 crore to Rs 167.55 crore. The company's authorised capital will increase to Rs 1,07.96 crore, divided into 10,79,60,000 shares valued at Rs 10 each. The total authorised post-bonus capital will rise to Rs 2 billion, divided into 20 million equity shares.

The company's financial performance in Q2FY26 showed an increase in revenue by 10.7% year-on-year to Rs 731 crore and a half-year revenue growth of 11% to Rs 1,400 crore compared to FY25. EBITDA rose by 10.8% in Q2 to Rs 224 crore and by 11.8% for the half-year ending September 30, reaching Rs 416 crore. Net profit improved by 16.4% in Q2 to Rs 152 crore and by 20% in the first half of FY26 to Rs 286 crore.

Dr. Lal Pathlabs' earnings per share (EPS) increased by 16.2% in Q2 to Rs 18.1 and by nearly 20% in H1FY26 to Rs 33.9, reflecting strong profitability and operational efficiency with stable margins around 30%. The company's robust financial performance underscores its ability to maintain steady growth.

Dr Lal Pathlabs News

On October 29, Dr. Lal PathLabs Limited received an Assessment Order and Demand Notice from the Income Tax Department for FY2017-18 on October 31, demanding a tax payment of Rs 2.43 crore due to specific additions and disallowances totalling Rs 2.79 crore. The company stated that this does not significantly impact its operations or financial standing and plans to appeal against the assessment.

Technical analyst Riyank Arora from Mehta Equities Ltd commented on Dr. Lal PathLabs' stock performance: "Dr. Lal PathLabs is exhibiting steady strength after consolidating near ₹3100 support. The stock is trading above key short-term moving averages, indicating renewed buying interest. RSI is trending upward, supporting bullish momentum. A sustained move above ₹3150 could drive the price toward ₹3230 and ₹3320. Maintain a stop-loss at ₹3050 for risk control."

The anticipated crediting or dispatching of bonus shares is expected within two months from the Board's approval date, likely by December 30, 2025. Investors are keenly observing these developments as they evaluate their investment strategies regarding Dr. Lal Pathlabs.